Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation

Xiaoqing Fan1,2,3,*, Junqi Fan1,2,5, Haoran Yang1,3,4, Chenggang Zhao1,2, Wanxiang Niu1,2, Zhiyou Fang1,4,5 and Xueran Chen1,4,5

© The Author(s) 2021, corrected publication 2021

INTRODUCTION

Human glioblastoma (GBM) is the most common and deadly of the primary intracranial tumors and its treatment continues to be merely palliative [1, 2]. Treatment targeting a single molecular pathway is ineffective for GBM because of its marked intratumor and intertumoral heterogeneity (including cellular and molecular complexity) [3, 4]. GBM contains glioblastoma stem cells (GSCs) that are highly resistant to radiotherapy and chemotherapy, which results in high recurrence rates [5, 6]. Targeting GSCs and identifying new markers are key issues in the development of innovative strategies to eradicate GBM.

Recent improvements in gene technology and application of whole-genome research have allowed identification of four molecular subtypes of GBM (namely, classical, proneural, neural, and mesenchymal), in patients based on The Cancer Genome Atlas (TCGA) [7, 8]. The neural subtype is now considered an artefact because this signature is thought to reflect the presence of normal neurons that reside within the tumor [7]. Classical GBM has a characteristic profile of highly proliferative cells and is responsive to conventional radiotherapy and chemotherapy, likely because the p53 DNA damage response is intact in these patients [7]. Isocitrate dehydrogenase 1 (IDH1) is the gene most commonly mutated in the proneural subtype of GBM [8, 9]. The mesenchymal subtype of GBM has a particularly prognosis that is characterized by an early tumor recurrence through therapeutic failure. Hyperactive transforming growth factor-beta (TGF-β) signaling could be a signature event in mesenchymal GBM, leading to dysregulation of downstream targets and contributing to malignant transformation [10, 11]. TGF-β increases glioma-initiating cell self-renewal via induction of leukemia inhibitor factor in human GBM and promotes proliferation via induction of platelet-derived growth factor-beta (PDGF-β) in gliomas with an unmethylated PDGF-β gene [12–14]. The plasticity of the transcription group in GBM allows transition from the proneural subgroup to the mesenchymal subgroup after cytotoxic treatment, and genomic analysis has not been successful in guiding the development of precision medicine for GBM [15, 16]. Therefore, there is an urgent need to identify therapeutic targets and novel biomarkers for these subsets and to investigate the regulatory mechanisms that are responsible for different GBM subsets considering GBM-specific niche contexts. In particular, activation of the TGF-β/Smad signaling pathway in the various subtypes of GBM and the role of this pathway in the transition of molecular subtypes are poorly understood.

Protein S-palmitoylation is a two-sided post-translational modification of proteins with fatty acids regulated by protein acyltransferases, which are characterized by a conserved Asp-His-Cys (DHHC) catalytic domain [17, 18]. Abnormalities in protein palmitoylation and dysregulation of DHHC proteins are involved in the development and progression of cancer [19–21]. ZDHHC5 palmitoylates EZH2 and modulates its methylation status in...
p53-mutant glioma [22], and inhibition of ZDHHC20 palmitoyltransferase results in dependence of cancer cells on the epidermal growth factor receptor for survival signals [23].

Here, we demonstrate that IDH1 mutation suppresses the TGF-β signaling pathway and that E2F4 interacts with Smad3 to inhibit expression of mesenchymal markers. However, Smad3 palmitoylation mediated by palmitoyltransferase ZDHHC19 promotes activation of the TGF-β signaling pathway, and its interaction with EP300 promotes expression of mesenchymal markers in the mesenchymal subtype of GBM.

**RESULTS**

IDH1 knockdown elevates HIF-1α and decreases TGF-β in proneural GBM cells

Notably, IDH1 mutations were identified in proneural GBM. Tumor-derived IDH1 mutations impair formation of the enzyme product, α-ketoglutaric acid (α-KG). α-KG is required by prolyl hydroxylases, which are enzymes that hydroxylate and promote the degradation of hypoxia-inducible factor 1-alpha (HIF-1α) [9]. We found that HIF-1α protein levels in the proneural (PN12) subtype of GBM stem cells were elevated in response to IDH1 knockdown (Fig. 1A).
Similarly, overexpression of the IDH1 R132H mutant increased HIF-1α protein levels in PN12 GSCs (Figs. 1B and S1A). However, octyl-α-KG suppressed induction of HIF-1α caused by overexpression of the IDH1 R132H mutant in PN12 GSCs (Fig. 1B and S1A). Analysis of reverse-phase protein array data for TCGA samples showed an increase in the level of HIF-1α in IDH1 R132H mutant GBM in comparison with that in wild-type IDH1 GBM (Fig. 1C). IDH1 knockdown or overexpression of the IDH1 R132H mutant-induced HIF-1α mRNA (Fig. 1D) might be due to aberrant methylation of HIF-1α (Fig. 1E). Moreover, TET2 knockdown would recover the decrease in methylation of HIF-1α mediated by IDH1 knockdown. Therefore, we concluded that a reduction in IDH1 activity produces a reduction in the α-KG level, which in turn leads to methylation and stabilization of HIF-1α.

Furthermore, the protein expression of TGF-β1 was significantly reduced in response to overexpression of HIF-1α in proneural (PN12) cells (Fig. 1F). Notably, knockdown or mutation of IDH1 did not affect the HIF-1α mRNA level (Fig. S1B) but only led to a decrease in TGF-β1 protein (Fig. S1C). We also monitored the degradation kinetics of endogenous TGF-β1 protein following overexpression of HIF-1α using the cycloheximide chase assay. The TGF-β1 protein level decreased at the beginning of treatment with cycloheximide, and its half-life was markedly shorter in cells that overexpressed HIF-1α than in control cells (2.5 h vs 5.0 h; Fig. 1G). Indeed, the decrease in TGF-β1 transcription in response to hypoxia was further confirmed by stabilizing HIF-1α with CoCl2 (100 μmol/l) and overexpression of HIF-1α (Fig. 1H). Thus, we found that HIF-1α regulates the transcription activity and stability of TGF-β1 protein. Overall, IDH1 mutation promotes higher HIF-1α levels in proneural GBM, which in turn can lead to a reduction in TGF-β1.

**Smad3 constitutes an important effector in both proneural and mesenchymal GSCs**

In view of the plasticity of the GBM transcriptional subgroups, these results prompted us to speculate that activation or inactivation of the TGF-β/Smad-signaling pathway might regulate the transformation of proneural GSCs into mesenchymal GSCs. Treatment with TGF-β1 did not change the levels of mesenchymal markers in proneural GSCs, although the expression levels of these markers were slightly reduced (Figs. 2A and S2A). However, the longer the duration of treatment with TGF-β1, the higher the gene expression profiles of mesenchymal markers in mesenchymal GSCs (Figs. 2A and S2A).

The functions of the TGF-β signaling pathway in the GBM subgroups were investigated at the molecular level by western blotting, which allowed analysis of the phosphorylation status of Smad2 and Smad3 in proneural and mesenchymal GBM cells. We found that mesenchymal cell lines (ME23, ME27, and ME29) showed a higher degree of activation of the TGF-β pathway than proneural cell lines (PN12, PN16, and PN19). In particular, treatment with TGF-β1 activated the TGF-β pathway more strongly in mesenchymal cell lines than in proneural cell lines (Fig. 2B). Overall, we demonstrated that neither treatment with TGF-β1 nor activation of the TGF-β pathway could induce proneural to mesenchymal transition.

We then performed single-sample gene set enrichment analysis and found that survival was significantly shorter in patients with mesenchymal GBM and a higher Smad3 gene signature (a gene transcriptionally related to Smad3) than in those with mesenchymal GBM and a lower Smad3 signature (p = 0.001; Fig. 2C).

Although there was a difference in activation of Smad3 between the proneural and mesenchymal GSCs, this protein was partly co-expressed in both cell types, indicating a likely association. Next, we investigated the complexes of Smad3 with other proteins using the anti-Smad3 antibody in both proneural and mesenchymal GSCs, and the components of the complexes were identified using liquid chromatography/tandem mass spectrometry. We analyzed the overlapping peaks in both the proneural and mesenchymal GSCs and identified those that were unique to a particular subtype of GSCs and those that were common to both proneural and mesenchymal GSCs. The protein–protein interaction networks were identified using STRING and Cytoscape software. Notably, proneural GSCs contained a Smad3–E2F4 complex whereas mesenchymal GSCs contained a Smad3–EP300 complex (Fig. 2D). Consistent with these findings, immunoprecipitation analysis confirmed interaction between Smad3 and E2F4 in proneural GSCs and the presence of Smad3 and EP300 complexes in mesenchymal GSCs (Fig. 2E). Moreover, co-immunoprecipitation and pull down of Smad3 demonstrated competitive interaction of E2F4 and EP300 with Smad3 (Fig. S2B and S2C).

E2F4 is a transcription suppression factor [24] and histone acetyltransferase EP300 is a transcription cofactor [25]. Therefore, we hypothesized that E2F4 interacts with Smad3 to suppress the expression of mesenchymal markers in proneural GSCs and that EP300 competitively interacts with Smad3 to activate expression of mesenchymal markers in mesenchymal GSCs.

**Palmitoylation of Smad3 promotes its association with the plasma membrane and activation of the TGF-β pathway**

Several recent studies have indicated that the DHHC (Asp-His-His-Cys)–S-acetyltransferase protein family and its substrates play an
important role in tumorigenesis, especially in the development and progression of glioma [22, 26, 27]. The CSS-Palm 4.0 software used in this study indicated that Smad3 has one potential palmitoylation site (Fig. 3A). To identify which protein S-acyltransferases were responsible for modification of Smad3, 23 HA-tagged ZDHHC protein S-acyltransferases were co-expressed with Flag-Smad3 (Fig. S3A). Smad3 palmitoylation was only detected following expression of ZDHHC4, 6, 11, 14, 19, and 23, with ZDHHC19 being the most efficient (Fig. 3B). Palmitoylation of Smad3 was substantially reduced in cells expressing C421A mutant Smad3 and diminished by silencing of ZDHHC19 (Figs. 3C and 3B). Notably, there was a positive association between activation of Smad3 and palmitoylation of Smad3 (Figs. 3C and S3B). The palmitoylation level of Smad3 was decreased by 2-BP (a palmitoylation inhibitor) and increased by PalmB (a de-palmitoylation inhibitor) (Fig. S3C). Furthermore, a Click-iT Labeling assay confirmed that Smad3 could be palmitoylated by ZDHHC19 (Fig. S3D). Consistent with these findings, ZDHHC19 expression levels and Smad3 palmitoylation levels were higher in mesenchymal cell lines than in proneural cell lines (Fig. 3D).

Fig. 2 Smad3 constitutes an important effector in both proneural and mesenchymal GSCs. A Heatmap showing the molecular subtype marker expression in proneural GSCs (PN12, PN16, and PN19), and mesenchymal GSCs (ME23, ME27, and ME29) with or without TGF-β1 treatment for 4 or 8 h. Proneural markers: DLL3, OLG2, ASCL1, CD133, and SOX2. Mesenchymal markers: CD44, CHI3L1, TIMP1, BCL3, COL3A1, MGP, and POSTN. Z-scores were calculated from the △Ct values obtained in the quantitative polymerase chain reaction analysis. B Western blotting analysis of SMAD2, p-SMAD2, SMAD3, and p-SMAD3 expression in proneural GSCs (PN12, PN16, and PN19) and mesenchymal GSCs (ME23, ME27, and ME29) with or without TGF-β1 treatment for 8 h. C Kaplan–Meier survival curves for patients with mesenchymal GBM and a high Smad3 gene signature (n = 44) and those with a low Smad3 gene signature (n = 33). D Protein–protein interaction networks indicated by STRING and Cytoscape software show overlapping peaks in both proneural and mesenchymal GSCs and also identify those that are unique to a particular subtype of GSCs or shared between the proneural and mesenchymal GSCs. E Lysates from proneural GSCs and mesenchymal GSCs were subjected to immunoprecipitation using anti-Smad3 antibody and then immunoblotted with anti-E2F4 and anti-EP300 antibodies. GSCs glioblastoma stem cells.
Moreover, the Smad3 palmitoylation mutant was unable to activate the TGF-β/Smad-signaling pathway (Fig. 3E). Thus, ZDHHC19 expression levels and Smad3 palmitoylation levels were identified as markers for the mesenchymal or proneural subtype.

We then assessed whether palmitoylation of Smad3 influenced its distribution/localization in GSCs. Both immunostaining and western blotting showed that GSCs transfected with the Smad3 C421A mutant constructs or infected with ZDHHC19 siRNA had reduced expression of Smad3 on the membrane surface and that those treated with the de-palmitoylation inhibitor PalmB maintained the same level of Smad3 in comparison with normal conditions (Figs. 3F and S3E). These findings indicate that palmitoylation of Smad3 helps Smad3 traffic in the membrane fractions and activates the TGF-β/Smad3 pathway.

Inhibition of HIF-1α is effective in the proneural subtype and inhibition of Smad3 is effective in the mesenchymal subtype

Depletion of E2F4, upregulation of ZDHHC19, or activation of Smad3 reduced expression levels of proneural markers in proneural GSCs and increased those of mesenchymal markers to varying degrees (Fig. 4A). Moreover, both proneural and mesenchymal markers were reduced after depletion of HIF-1α or treatment with the HIF-1α inhibitor, GN44028 (Figs. 4A and S4). In mesenchymal GSCs, depletion of ZDHHC19 or inactivation of Smad3 reduced the expression levels of mesenchymal markers with no change in levels of proneural markers (Figs. 4A and S4).

The mesenchymal GSCs displayed preferential sensitivity to treatment with C646 (an EP300 inhibitor), 2-BP (a palmitoylation inhibitor), or (E)-SIS3 (a Smad3 inhibitor), similar to the effect of ZDHHC19 depletion (Figs. 4A and S4).

To leverage our findings for clinical application, we examined the sensitivity of proneural GSC subtypes to HIF-1α inhibitors and the sensitivity of mesenchymal subtypes to palmitoylation inhibitors or Smad3 inhibitors. Notably, depletion of E2F4, upregulation of ZDHHC19, or activation of Smad3 increased the viability (Fig. 4B) and self-renewal (Fig. 4C) of proneural GSCs, whereas inactivation of HIF-1α blocked these effects. In mesenchymal GSCs, depletion of ZDHHC19, inactivation of Smad3, inactivation of EP300, or inhibition of palmitoylation could reduce cell viability (Fig. 4D) and self-renewal (Fig. 4E).

Next, we examined the therapeutic effects of HIF-1α, EP300, Smad3, and a palmitoylation inhibitor in mice bearing intracranial tumors derived from proneural or mesenchymal GSCs (Fig. 5). Inhibition of HIF-1α activity extended the survival rate of animals with implanted proneural GSCs more efficiently than in animals that were not treated with GN44028. Moreover, inhibition of palmitoylation or (E)-SIS3 injection resulted in inhibition of tumor growth and extended survival in all animals with implanted mesenchymal GSCs. We also investigated the effects of treatment with these inhibitors as monotherapy or in combination in xenografts containing a mixture of both proneural and mesenchymal GSCs in vivo. The results indicated that combinatorial
inhibition of HIF-1α and Smad3 activity is an effective treatment strategy for heterogeneous subtypes of GBM. Moreover, both proneural and mesenchymal markers were reduced after treatment with the HIF-1α inhibitor, GN44028 (Fig. S5A). 2-BP or (E)-SIS3 could reduce the expression levels of mesenchymal markers with only a slight change in levels of proneural markers (Fig. S5A). These findings may be related to Smad3 palmitoylation or the phosphorylation level (Fig. S5B). In summary, we found that in proneural GSCs, IDH1 mutation promotes higher HIF-1α levels and reduces expression of TGF-β1...
and activation of the TGF-β signaling pathway. The transcription suppression factor E2F4 interacts with Smad3 to suppress the expression of mesenchymal markers. However, palmitoylation of Smad3 mediated by the palmitoyl transferase ZDHHC19 promotes its association with the cytoplasmic membrane and its S423,425 phosphorylation in mesenchymal GSCs. Finally, palmitoylated and phosphorylated Smad3 translocates into the nucleus and interacts with EP300 to promote expression of mesenchymal markers. Furthermore, combinatorial inhibition of HIF-1α and Smad3 activity is an effective treatment strategy for heterogeneous subtypes of GBM (Fig. 6).

DISCUSSION

Tumor cell heterogeneity is caused by variations in genetics, epigenetic cell states, and microenvironments. In this study, we found that IDH1 mutation-induced activation of HIF-1α and reduced expression of TGF-β1 in proneural GSCs and that Smad3 co-interacted with E2F4 to inhibit expression of mesenchymal markers. In mesenchymal GSCs, we identified a mechanism that could regulate activation of Smad3 through palmitoylation of the Smad3 C-terminal tail. Palmitoylation facilitates activation of Smad3 via membrane positioning and phosphorylation via TGF-β1/2. Blocking the activity of HIF-1α and that of Smad3 could be effective against the proneural and mesenchymal subtypes of GBM, respectively.

According to the molecular signature, GBM is divided into four subtypes (proneural, neural, classical, and mesenchymal), each of which has its own hereditary background. In one study, 41% of primary GBM cases were identified as the mesenchymal subtype and only 15% as the proneural subtype; however, the ratio of subtypes was the opposite for secondary GBM (mesenchymal, 15%; proneural, 44%) [28]. Mutations in IDH1 were found to be more common in the proneural subtypes. IDH1 gene mutations in glomas exhibit two unique features: lack of loss of heterozygosity and lack of apparent inactivating mutations such as truncations or frame shifts [29].

Tumor-derived mutant IDH1 suppresses wild-type IDH1 mainly by forming a catalytically inactive heterodimer, leading to a decline in cellular a-KG [9]. This reduction is produced by a decrease in the activity of IDH1 at the a-KG level, which in turn can lead to stabilization of HIF-1α. Proneural GMBs are markers of mature vessels. IDH1-mutated gliomas also exhibit an increase in levels of vascular endothelial growth factor when compared with gliomas without IDH1 mutations of similar type and grade [30].

Moreover, we found that HIF-1α interferes with signal transduction of TGF-β1 by reducing mRNA and protein expression of TGF-β1 and by reducing Smad3 phosphorylation. However, these findings are not consistent with other reports. First, the TGF-β1/Smad3 signaling pathway has been found in hypoxia-activated fibroblasts and the chromatin immunoprecipitation assay identified the presence of hypoxia response elements in the TGF-β1 promoter in mesenchymal stem cells [31]. Second, a study in rodent mandibular osteoblasts found that expression of TGF-β1 was shown to have undergone a state of hypoxia, which gradually decreased when the duration of hypoxia was prolonged [32]. Therefore, it is obvious that HIF-1α can induce expression of TGF-β1 in several types of cells and at different stages of cell growth. However, HIF-1α can also inhibit the expression of TGF-β1. In human fetal osteoblasts, hypoxia could lead to decreased expression of TGF-β1 [33], which is consistent with our present findings. Reverse expression of the inhibitory signal transduction from HIF-1α to TGF-β1 expression and phosphorylation of Smad3 showed the self-correction between TGF-β1 and HIF-1α in GSCs.

Mesenchymal GBM also expresses markers for hypoxia in the microvasculature [16]. Activation of the TGF-β pathway was found to be strongly associated with the mesenchymal subtype [34, 35]. Therefore, in the mesenchymal subtype of GBM, there is another way to regulate the TGF-β signaling pathway. Palmitoylation is required for intracellular transport, cell membrane positioning, and phosphorylation of Smad3. The lower activation of the TGF-β signaling pathway may be accounted for by the defect in membrane localization of Smad3, which is observed in ZDHHC19-silenced proneural cells. Our findings suggest that intracellular transport and cell membrane positioning provide a platform for Smad3 to be phosphorylated by TGF-β1/2 at the plasma membrane and signal within endosomal compartments.

For proneural GSCs, pharmacologic blockade of HIF-1α activity by GN44028 and of Smad3 activity by the Smad3 inhibitor, (E)-SIS3 or a palmitoylation inhibitor, 2-BP, effectively suppressed tumor growth and extended survival rates in animals with xenografts. Combinatorial therapy achieved the most effective control of both mesenchymal and proneural tumors, although monotherapy alone targeted to Smad3 or HIF-1α hindered tumor growth near the detection limits. GBM cells can undergo transitions in molecular subtype in response to chemotherapy or radiotherapy and according to the microenvironment of the tumor, which may lead to differences in effects between in vitro and in vivo experiments using HIF-1α and Smad3 inhibitors.

In summary, we found that mutation of IDH1 and activation of HIF-1α are significant signatures in proneural cells whereas activation of the TGF-β/Smad3 signaling pathway is characteristic of the mesenchymal subtype. Thus, the activity of Smad3 and HIF-1α could represent the main molecular targets for treatment of gliomas because these proteins may coordinate the basic aspects of cancer stem cell biology. Further studies are needed to determine how the interconversion of different pools of GSCs may support adaptive resistance to targeted therapies.

MATERIALS AND METHODS

Reagents, antibodies, and plasmids

The α-KG (7S980) and palmitate analog inhibitor 2-bromopalmitate (2-BP, 238422) were purchased from Sigma-Aldrich (St Louis, MO, USA). The HIF-1α inhibitor GN44028 (HY-110266), Smad3 inhibitor, (E)-SIS3 (HY-13013), and EP300 inhibitor C646 (HY-13823) were obtained from MedChemExpress (Monmouth Junction, NJ, USA).

ZDHHC19 (orb186631) was sourced from Biorbyt Ltd (Cambridge, UK), Smad3 (9523), E2F4 (40291), EP300 (54062), and β-actin (3700) were purchased from Cell Signaling Technology (Beverly, MA, USA). Flag-tag (F1804) and HA-tag (H9658) were obtained from Sigma-Aldrich.

Full-length IDH1, HIF-1α, or Smad3 cDNA was cloned into a pcDNA3.0 expression vector (Invitrogen, Waltham, MA, USA) for the overexpression...
Fig. 5  In vivo therapeutic efficacy of pharmacologic inhibitors of HIF-1α and Smad3 used alone or in combination in a single subtype model and a mixed glioblastoma model. A Kaplan–Meier survival curves for mice bearing a single subtype of tumor and mice bearing a mixed orthotopic tumor with PN12 and ME23 cells that were treated with 10 mg/kg GN44028, 7.5 mg/kg 2-BP, and 15 mg/kg (E)-SIS3 alone or in combination (n = 15 per group). Log-rank p-values were used to determine statistical significance. *p < 0.05. B Tumor weight in mice with a single subtype of tumor and mice with a mixed orthotopic tumor with PN12 and ME23 cells treated with 10 mg/kg GN44028, 7.5 mg/kg 2-BP, and 15 mg/kg (E)-SIS3 alone or in combination (n = 5 per group) after 6 weeks.

Immunoprecipitation, the ABE labeling method, and western blot analysis
Protein–protein interactions were detected using a Pierce Crosslink magnetic IP and Co-IP kit (Thermo Scientific). The immunoprecipitated and co-immunoprecipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, respectively.

Cell viability assays
Cell viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instructions.

In vitro tumoursphere formation
For suspension culture/tumoursphere formation, 50, 100, 250, 500, 750, and 1000 cells were seeded in 96-well plates containing 200 μl of complete neurobasal medium. After 10 days, the tumourspheres were measured and analyzed.

Animal experiments
This component of the study was approved by the institutional review board of Hefei Cancer Hospital, Chinese Academy of Sciences (approval number, SWXY-Y-2020-08). All animal experiments were performed according to the guidelines of the Animal Use and Care Committees at the Hefei Institutes of Physical Science, Chinese Academy of Sciences (approval number, SWXY-DW-2020-02).

For the implantation study, a stereotactic method was utilized to inject a suspension of 500 PN12 or/and 500 ME23 GSCs in phosphate-buffered saline with high glucose into the hemi-striatum of 6-week-old BALB/c mice (female, 20–30 g) after anesthesia with ketamine (132 mg/kg) and xylazine (8.8 mg/kg). The following coordinates were used: dorsoventral, −3.5 mm; mediolateral, −2.5 mm; and anteroposterior, r = 0. After 1 week, an HIF-1α inhibitor (GN44028, 10 mg/kg), palmitoylation inhibitor (2-BP, 7.5 mg/kg), and co-immunoprecipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, respectively.

Cell lysates were quantified by bicinchoninic acid assay, resolved by SDS-PAGE, and transferred onto a nitrocellulose blotting membrane (Bio-Rad Laboratories, Hercules, CA, USA) that was subsequently incubated with primary antibodies. Finally, the membranes were exposed to the corresponding horseradish peroxidase-conjugated secondary antibodies (Bio-Rad), and the bands were detected using enhanced chemiluminescence (ECL).
and/or Smad3 inhibitor [(E)-SIS3, 15 mg/kg] was administered orally by gavage. Finally, the tumor-bearing mice were sacrificed by injection of sodium pentobarbital (50 mg/kg) and analyzed.

**Patient dataset analysis and gene set enrichment analysis**

The enrichment score was developed by single-sample gene set enrichment analysis (GSEA; ssGSEA: [https://www.broadinstitute.org/gsea/](https://www.broadinstitute.org/gsea/), a knowledge-based approach for interpreting genome-wide expression profiles, was performed as described elsewhere [38].

**Statistical analysis**

All data are presented as the mean ± standard error of the mean. Differences between groups were examined for statistical significance by one-way analysis or the Student’s $t$-test using GraphPad Prism software and the log-rank test was calculated using Excel software. Kaplan–Meier survival curves were generated using GraphPad Prism software, and the log-rank $p$-value was used to determine statistical significance. All experiments were repeated in each specimen presented in at least three biological duplicates (patient-derived xenograft cell models) with technical triplicates.

**REFERENCES**

1. McFalone-Figueroa JR, Lee EO. Brain tumors. Am J Med. 2018;131:874–82.
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.
3. Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases. Semin Cancer Biol. 2020;60:262–73.
4. Balca-Silva J, Matias D, Carmao AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: implications in resistance and therapeutic strategies. Semin Cancer Biol. 2019;58:130–41.
5. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.
6. Shafizad F, Ghasemi S, Verdi J, Mardpour S, Mollapour Sisakht M, Azizi Z, et al. Glioblastoma cancer stem cell biology: potential theranostic targets. Drug Resist Updat. 2019;42:35–45.
7. Van Meir EG, Hadijaswanty CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166–93.
8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
9. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261–5.
10. Zhang M, Kleber S, Rührich M, Timke C, Han N, Tuftonberg J, et al. Blockade of TGF-β signaling by the TGFβRI kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71:7155–67.
11. Jiang Y, Zhou J, Hou D, Luo P, Gao H, Ma Y, et al. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway. J Pathol. 2019;249:26–38.
12. Anido J, Sáez-Borderías A, González-Juncà A, Roldán L, Folch G, Carmona MA, et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18:655–68.
13. Bruna A, Darken RS, Rojo F, Ocáriz A, Peñuelas S, Arias I, et al. High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11:147–60.
14. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, et al. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15:315–27.
15. Pavlyukov MS, Yu H, Bastola S, Minata M, Shender VO, Lee Y, et al. Apoptotic cell-derived extracellular vesicles promote malignancy of glioblastoma via intercellular transfer of splicing factors. Cancer Cell. 2018;34:119–35 e110.
16. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19:4392–403.
17. Tsutsumi R, Fukuta Y, Fukuta M. Discovery of protein-palmitoylating enzymes. Pflug Arch. 2008;456:1199–206.
18. El-Agnaf OM. Protein lipidation. FEBS J. 2007;274:5202–10.
19. De I, Sadiukhkan S. Emerging roles of DHHC-mediated protein palmitoylation in physiological and pathophysiological context. Eur J Cell Biol. 2018;97:319–38.
20. Korycka J, Lach A, Heger E, Boguslawska DM, Wolny M, Toporikiewicz M, et al. Human DHHC proteins: a spotlight on the hidden player of palmitoylation. Eur J Cell Biol. 2012;91:107–17.
21. Tools. MD. Palmitoylation of proteins in cancer, Biochem Soc Trans. 2017;45:409–16.
22. Chen X, Ma H, Wang Z, Zhang S, Yang H, Fang Z. EZH2 palmitoylation-mediated by ZDHHC5 in p53-mutant glioma drives malignant development and progression. Cancer Res. 2017;77:4998–5010.
23. Runkle KB, Khambadka A, Stypulkowski E, Cao XJ, Wang W, Garcia BA, et al. Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling. Mol Cell. 2016;62:385–96.
ACKNOWLEDGEMENTS

We thank the members of the technical assistance team at the Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences. We also thank Dr. Fukata for providing the 23 plasmids encoding the HA-tagged ZDHHC family proteins.

AUTHOR CONTRIBUTIONS

ZYF and XRC conceived and designed the experiments; XQF, JQF, HRY, CGZ, and WXN performed the experiments; XQF, HRY, and XRC analyzed the data; XRC, XQF, and CGZ wrote the paper. All authors read and approved the final manuscript.

FUNDING

This research was supported by the National Natural Science Foundation of China (grant numbers 82172663, 82104208, 81772066, 81773131, and 81972635), the Youth Innovation Promotion Association of the Chinese Academy of Sciences (grant number 2018487), and National Key R&D Program of China (grant number 2017YFA0503600).

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

The study was approved by the institutional review board of Hefei Cancer Hospital, Chinese Academy of Sciences (approval number, SWYX-Y-2020-08). All animal experiments were performed according to the guidelines of the Animal Use and Care Committees at the Hefei Institutes of Physical Science, Chinese Academy of Sciences (approval number, SWYX-DW-2020-02).

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at http://www.nature.com/articles/s41389-021-00361-8.

Correspondence and requests for materials should be addressed to Zhiyou Fang or Xueran Chen.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.